Figure 2. Rates of serious infectious events (SIEs) in the double-blind, placebo-controlled periods.
Multiple occurrences of the same event in one individual were counted multiple times. MTX, methotrexate; OCR200, ocrelizumab 200 mg×2; OCR500, ocrelizumab 500 mg×2; PBO, placebo; pt-yrs, patient-years.